Cost-effectiveness of antiemetics use during cancer chemotherapy

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 3, 2003, Pages 263-272

  Lachaine, Jean ^a   Crott, Ralph ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

Antiemetics; Chemotherapy; CINV; Cost effectiveness; Emesis; Serotonin antagonists

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; GRANISETRON; METHAZOLAMIDE; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; SEROTONIN ANTAGONIST; TROPISETRON; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; NAUSEA AND VOMITING; QUALITY ADJUSTED LIFE YEAR; RADIATION INDUCED EMESIS; REVIEW; SIDE EFFECT;

EID: 0038680487     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.3.263     Document Type: Review

References (46)

1. Coates A, Abraham S, Kaye SB et al. On the receiving end: patient perception of the side effects of cancer chemotherapy. Eur. J. Cancer. Clin. Oncol. 19(2), 203-208 (1983).
2. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N. Engl. J. Med. 340(3), 190-195 (1999).
3. Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 9(5),350-354 (2001).
4. Gralla RJ. New agents, new treatment and antiemetic therapy. Semin. Oncol. 29(1Suppl. 4), 119-124 (2001).
5. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 18(2), 163-173 (2000).
6. Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338(8765), 483-487 (1991).
7. O'Brien BJ, Rusthoven J, Rocchi A et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 149(3), 296-302 (1993).
8. Tanneberger S, Lelli G, Martoni A, Piana E, Pannuti F. The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). J. Chemotherapy 4(5), 326-331 (1992).
9. Johnson N, Bosanquet N. Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer drugs 6(2), 243-249 (1995).
10. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J. Clin. Oncol. (1), 344-351 (1999).
11. Ballatori E, Roila F, Berto P et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. PharmacoEconomics 5(3), 227-237 (1994).
12. Buxton MJ, O'Brien BJ. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Brit. J. Cancer 19, S64-S67 (1992).
13. Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N. Engl. J. Med. 322(12), 816-821 (1990).
14. Cox F, Hirsch J. Ondansetron: a cost-effective advance in antiemetic therapy. Oncology 50(3), 186-190 (1993).
15. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49(4), 295-304 (1992).
16. Cunningham D, Gore M, Davidson N, Miocevich M, Manchanda M, Wells N. The real costs of emesis-an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur. J. Cancer 29A(3), 303-306 (1993).
17. Kwong WJ, Parasuraman TV. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. Phar. Pract. Manag. Q. 19(1), 28-41 (1999).
18. Lachaine J, Laurier C, Langleben A, Vaillant L. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Crit. Rev. Oncol. Hematol. 32(2), 105-112 (1999).
19. Lachaine J, Laurier C. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. Am. J. Health Syst. Pharm. 59(19), 1837-1846 (2002).
20. Sands R, Roberts JT, Marsh M, Gill A. Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis. J. Clin. Oncol. 4(1), 67 (1992).
21. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am. J. Hospital Pharmacy 51(12), 1555-1563 (1994).
22. Grunberg SM. Cost-effective use of antiemetics. Oncology 12(3 Suppl. 4), 38-42 (1998).
23. Dranitsaris G, Leung P, Ciotti R et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. PharmacoEconomics 19(9), 955-967 (2001).
24. Tejedor I, Idoate A, Jimenez M, Sierrasesumaga L, Giraldez J. Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children. Pharm. World Sci. 21(2), 60-68 (1999).
25. Barrajon E, de las PR. Randomised double-blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Support Care Cancer 8(4), 323-333 (2000).
26. Becker AJ, Mutnick AH, Ross MB, Stilwell AA, Riggs CE, Hanson DB. Combining a clinical trial with decision analysis to evaluate antiemetic agents. Formulary 31(August), 670-683 (1996).
27. Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. Ann. Pharmacotherapy 34(10), 1101-1108 (2000).
28. Bonneterre J, Hecquet B. Granisetron (intravenous) compared with ondansetron (intravenous plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer 82(12), 1038-1043 (1995).
29. Noble A. Bremer K, Goedhals L, Cupissol D, Dilly SG. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5 day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur. J. Cancer 30A(8), 1083-1088 (1994).
30. Zeidman A, Bendayan D, Benzion T, Kaufman O, Cohen AM, Mittelman M. Granisetron and ondansetron for chemotherapy-related nausea and vomiting. Haematologia 29(1),25-31 (1998).
31. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J. Clin. Oncol. 17(9), 2971-2994 (1999).
32. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 15(1), 103-109 (1997).
33. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann. Oncol. 14(2), 291-297 (2003).
34. Dranitsaris G, Burry L, Leung P. Using decision analysis modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist anti-emetics. Proceedings of 12th International Symposium: Supportive Care in Cancer. Washington DC, USA (2000).
35. Johnson NE, Nash DB, Carpenter CE, Sistek CJ. Ondansetron: costs and resource utilisation in a US teaching hospital setting. PharmacoEconomics 3(6), 471-481(1993).
36. Crucitt MA, Hyman W, Grote T et al. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin. Ther. 18(4), 778-788 (1996).
37. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intra venous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J. Clin. Oncol. 10(12), 1969-1975 (1992).
38. Hainsworth J, Harvey W, Pendergrass K et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J. Clin. Oncol. 9(5), 721-728 (1991).
39. Hesketh PJ, Murphy WK, Lester EP et al. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J. Clin. Oncol. 7(6), 700-705 (1989).
40. Kris MG, Gralla RJ, Tyson LB et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55(3), 527-534 (1985).
41. Kris MG, Gralla RJ, Clark RA, Tyson LB. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J. Natl. Cancer Inst. 81(1), 42-46 (1989).
42. Kris MG, Clark RA, Tyson LB, Hahne WF, Pisters KM, Gralla RJ. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin greater or equal to 100 mg/m2. Am. J. Clin. Oncol. 16(1), 77-80 (1993).
43. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N. Engl. J. Med. 322(12), 810-816 (1990).
44. Marty M, Droz JP, Pouillart P, Paule B, Brion N, Bons J. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother. Pharmacol. 23(6), 389-391 (1989).
45. Onsrud M, Moxnes A, Sollien A, Grande T, Solesvik O. High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. Cancer 61(12), 2429-2432 (1988).
46. Roila F, Tonato M, Basurto C et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat. Rep. 69(12), 1353-1357 (1985).